Immix Biopharma
Immix Biopharma

Immix Biopharma

Biotechnology
WebsiteInvestor RelationsSEC
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

$576.6M

Market Cap • 11/6/2026

2012

(14 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

2,5

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

3,2

EPS

—

Market Cap

Market Cap

576,6M

EV

345,5M

EV/Revenue

0

EV/EBITDA

-8,4

EV/EBIT

-8,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-45,4%

Total Yield

-45,4%

Payout

0%

Retained Earnings

-126,1M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

121,3%

Capex/OCF

-1,5%

SBC/OCF

—

% PPE

1,4%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

129,9%

CAGR Net Income 5Y

80,1%

CAGR EPS 5Y

7,1%

CAGR OCF 5Y

157,9%

Leverage

N.D./EBITDA

5,6

Debt/Equity

0%

Current Ratio

25,1

Quick Ratio

25

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium